Interesting interview - pretty overarching view of the Q3 revenue growth and sounds like it's sustainable.
Good update on Halucnex too - if the clinical trials continue on this trajectory it could be a gamechanger.
But the big takeaway was the question relating revenue growth to share price. Surely this level of sustained revenue growth translates into some uplift in the SP?
Interesting interview - pretty overarching view of the Q3...
Add ME1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.009(42.9%) |
Mkt cap ! $1.093M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 3.0¢ | 2.1¢ | $45.97K | 1.691M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 81000 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 142367 | 3 |
View Market Depth
| Last trade - 15.59pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.9¢ |
Change
0.009 ( 164 %) |
||||
| Open | High | Low | Volume | ||
| 2.3¢ | 2.9¢ | 2.3¢ | 368036 | ||
| Last updated 15.51pm 17/06/2024 ? | |||||
| ME1 (ASX) Chart |
